Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNMORISE: mosunetuzumab + polatuzumab vedotin for early relapsed/refractory aggressive B-cell lymphoma after first-line polatuzumab-containing therapy
jRCTs041260113Phase 2Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mosunetuzumab and polatuzumab vedotin in aggressive B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and 1 more, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Overall response rate. Started Aug 2026; status: recruiting.
02
Drugs
mosunetuzumabpolatuzumab vedotin
03
Conditions
aggressive B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on jRCTs041260113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041260113.